Fig. 6.
Blocking MCP-1 increases the survival of SCID mice bearing MDA-231 human breast carcinoma cells.
MDA231 human breast cancer cells (3 × 105) were injected intravenously on day 1. Antibodies, including rabbit IgG and anti-MCP-1 (25 μg/mouse, 1 mg/kg), were given intraperitoneally to the mice on days 4, 8, 12, 16, 20, 24, and 28. Ten mice were included in each group. Their survival was monitored daily. The differences in the median values among the 2 groups are greater than would be expected by chance. There is a statistically significant difference (P < .024) as assessed by the log-rank test. One representative experiment of 3 experiments is shown.
